Clinical trial NCT00627796 - References

Acromegaly — Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly

Citation(s)

•   Alexopoulou O, Abrams P, Verhelst J, Poppe K, Velkeniers B, Abs R, Maiter D
  Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol. 2004 Sep;151(3):317-24.
•   Antonijoan RM, Barbanoj MJ, Cordero JA, Peraire C, Obach R, Vallès J, Chérif-Cheikh R, Torres ML, Bismuth F, Montes M
  Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunt
•   Ashwell SG, Bevan JS, Edwards OM, Harris MM, Holmes C, Middleton MA, James RA
  The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol. 2004 Apr;150(4):473-80.
•   Bevan JS
  Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab. 2005 Mar;90(3):1856-63. Epub 2004 Dec 21. Review.
•   Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Laurberg P, Pico AM, Valimaki M, Zgliczynski W
  Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab. 2002 Jan;87(1):99-104.
•   Colao A, Martino E, Cappabianca P, Cozzi R, Scanarini M, Ghigo E; A
  L.I.C.E. Study Group. First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Stu
•   Lucas T, Astorga R; Spanish-Portuguese Multicentre Autogel Study Group on Acromegaly
  Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clin
•   Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A
  A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab. 2005 Jul;90(7):4405-10. Epub
•   Ronchi CL, Boschetti M, Degli Uberti EC, Mariotti S, Grottoli S, Loli P, Lombardi G, Tamburrano G, Arvigo M, Angeletti G, Boscani PF, Beck-Peccoz P, Arosio M; Italian Multicenter Autogel Study Group in Acromegaly
  Efficacy of a slow-release formulation of
•   van Thiel SW, Romijn JA, Biermasz NR, Ballieux BE, Frölich M, Smit JW, Corssmit EP, Roelfsema F, Pereira AM
  Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eu

A Multicenter, Open, Prospective, Observational Study to Investigate the Effect of Lanreotide Autogel 120 mg on Control of GH and IGF-I Excess and Tumor Shrinkage in Newly Diagnosed Patients With Acromegaly

Details for clinical trial NCT00627796